Benitec Biopharma Limited: Presentation, CEO Sessions Sydney

Company Presentations

by Carolyn Herbert

Benitec Biopharma is currently engaged in commercialising a technology that was developed at the CSIRO, that we think is truly exquisite.  It has the capability to be almost disruptive in the way diseases are treated.
 
We call the technology DNA directed RNA interference, or DDRNAi for short. The technology has the capability to cure a wide range of of human diseases, typically with one single injection. 
 
The company is dual-listed, here in Australia on the ASX and back in August this year the company completed a raising in the United States and a listing on the Nasdaq.

Carolyn Herbert

Finance News Network
Carolyn joined FNN in August 2015 as the Head of News and also presented the Market at Midday and the Market Wrap. With more than five years of broadcast journalism experience, Carolyn has worked as a finance anchor on the Sky News Business channel and as an anchor and reporter for ABC News. She is also a qualified corporate lawyer specialising in IPOs, takeovers and mergers and acquisitions.

Are you a 708 sophisticated investor?

If you are a sophisticated investor as defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

We can alert you to wholesale investment opportunities not available to regular investors.

Please subscribe if you would like to be alerted to these types of opportunities.